3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
Other solid neoplasm
2
Head & Neck
2
Genitourinary
2
Endocrine
2
CNS
2
Thoracic
1
NET
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Trastuzumab
9
Paclitaxel
8
Capecitabine
8
trastuzumab deruxtecan
7
Fulvestrant
7
pertuzumab
5
eribulin
5
Gemcitabine
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
Doxorubicin
4
Carboplatin
4
Ado-Trastuzumab Emtansine
4
sacituzumab govitecan
3
ribociclib
3
Vinorelbine
3
Epirubicin
3
Docetaxel
3
selpercatinib
2
pembrolizumab
2
palbociclib
2
olaparib
2
neratinib
2
larotrectinib
2
exemestane
2
capivasertib
2
abemaciclib
2
Letrozole
2
Fluorouracil
2
Anastrozole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
entrectinib
×
Breast
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA